1-6 of 6
Jill Weisenbach
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

P62SQSTM1 Affects Interacting Substrates MDM2, MDMX and Casein Kinase 1alpha to Yield Protection of Beta-Catenin Along with p53 Silencing for Refractory AML

Justin Layer, Sravanti Rangaraju, Santhosh Pasupuleti, Larry D. Cripe, Hamid Sayar, Katie J Sargent, Jill Weisenbach, Huda S. Salman, G. David Roodman, Linsey Mayo, Reuben Kapur, Utpal P Dave', H. Scott Boswell
Journal: Blood
Blood (2022) 140 (Supplement 1): 11546–11547.
https://doi.org/10.1182/blood-2022-156329
Published: 2022
Journal Articles

Final Results of Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib in Acute Myeloid Leukemia with FLT3-ITD Mutation or Poor-Risk Cytogenetics

Antoine N Saliba, MD, H. Scott Boswell, MD, Larry D Cripe, MD, Mohammad Issam Abu Zaid, MBBS, Jill Weisenbach, RN, OCN, Hamid Sayar, MD MSc
Journal: Blood
Blood (2017) 130 (Supplement 1): 3897.
https://doi.org/10.1182/blood.V130.Suppl_1.3897.3897
Published: 2017
Journal Articles

Phase I Study of Recombinant Human Interleukin-18 (IL-18) in Combination with Ofatumumab after Autologous Peripheral Blood Stem Cell Transplantation (PBSCT) for Lymphoma

Michael J. Robertson, MD, Lijun Ni, BS (Life Sci. Clin. MD), Jill Weisenbach, RN, BSN, David Pelloso, Nagendra K. Prasad, BVSc, PhD MBA
Journal: Blood
Blood (2015) 126 (23): 5102.
https://doi.org/10.1182/blood.V126.23.5102.5102
Published: 2015
Journal Articles

Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib in Acute Myeloid Leukemia with FLT3-ITD Mutation or Monosomy 5, 7, or Complex Cytogenetics

Mohammad Abu Zaid, MBBS, H. Scott Boswell, MD, Larry D. Cripe, MD, Yan Liu, PhD, Jill Weisenbach, BS, Hamid Sayar, MD MS
Journal: Blood
Blood (2014) 124 (21): 976.
https://doi.org/10.1182/blood.V124.21.976.976
Published: 2014
Journal Articles

Phase I Trial Evaluating the Safety and Biological Activity of Iboctadekin (rhIL-18) in Combination with Rituximab in Patients with CD20+ B Cell Non-Hodgkin's Lymphoma,

Michael J. Robertson, MD, John Bauman, Olivia Gardner, Zdenka Jonak, Herbert Struemper, Fiona Germaschewski, Kevin M. Koch, Sharon Murray, Jill Weisenbach, RN, John Toso, MD, MSc
Journal: Blood
Blood (2011) 118 (21): 3697.
https://doi.org/10.1182/blood.V118.21.3697.3697
Published: 2011
Journal Articles

Cyclic Administration of Combination of Sorafenib and Vorinostat In Poor-Risk AML: A Pharmacodynamically-Oriented Extended Phase I Trial

Hamid Sayar, MD, Larry Cripe, MD, Mary Cangany, Jill Weisenbach, RN, OCN, Katie J. Sargent, RN, Chirayu Goswami, PhD., Lang Li, PhD., Annique Wilson-Weekes, MS, Rajasubramaniam Shanmugam, PhD, H. Scott Boswell, MD
Journal: Blood
Blood (2010) 116 (21): 3272.
https://doi.org/10.1182/blood.V116.21.3272.3272
Published: 2010